Chemomab Therapeutics Ltd

Chemomab Therapeutics Ltd operates with a current market capitalization of $12.24 million and a price-to-book ratio of 0.92, indicating that the company is trading at a discount relative to its book value. The company's liquidity position is characterized by a current ratio of 3.83, suggesting a strong ability to meet short-term obligations with its current assets. The company holds $4.67 million in cash and equivalents, which is a significant portion of its total assets of $18.01 million.

The company's profitability is currently negative, with an operating loss of $4.05 million and a net loss of $3.87 million. This results in a return on equity of -29.02% and a return on assets of -21.48%, both of which are below the industry median for biotechnology firms. The company's debt-to-equity ratio is 0.0, indicating that it is not leveraging debt to finance its operations.

Chemomab Therapeutics Ltd does not disclose segment or geographic revenue breakdowns in its latest financial filings, making it difficult to assess the concentration of its revenue sources. The absence of such data limits the ability to evaluate the company's exposure to specific markets or product lines.

The company's growth trajectory is uncertain, as it has not provided forward-looking revenue guidance in its latest filings. Analysts have assigned a mean price target of $15.00, with a median of $15.00 and a high of $25.00, indicating a wide range of expectations. The mean recommendation of 1.50 suggests a generally positive outlook, with one strong-buy and one buy rating.

The risk assessment for Chemomab Therapeutics Ltd indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is currently free of long-term debt, and its equity base is supported by $13.33 million in total equity. However, the company's negative net income and operating income suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders.

Recent events related to Chemomab Therapeutics Ltd include the publication of its latest financial results, which show continued losses and a reliance on cash reserves. The company has not disclosed any major strategic initiatives or product launches in its recent filings, and there are no indications of significant regulatory or legal challenges.

Operating income +38,6% YoY; Net income +36,8% YoY.

• ▍Operating income +38,6% YoY
• ▍Net income +36,8% YoY

Operating income +50,3% YoY; Net income +50,0% YoY.

• ▍Operating income +50,3% YoY
• ▍Net income +50,0% YoY

Operating income +40,0% YoY; Net income +43,4% YoY.

• ▍Operating income +40,0% YoY
• ▍Net income +43,4% YoY

Operating income +13,9% YoY; Net income +14,1% YoY.

• ▍Operating income +13,9% YoY
• ▍Net income +14,1% YoY

Operating income -$3.7M.

• ▍Operating income -$3.7M

Operating income -$3.8M.

• ▍Operating income -$3.8M

Operating income -$4.0M.

• ▍Operating income -$4.0M

Operating income +35,1% YoY; Net income +35,5% YoY.

• ▍Operating income +35,1% YoY
• ▍Net income +35,5% YoY
• ▍Free cash flow +35,7% YoY

Operating income +42,1% YoY; Net income +42,4% YoY.

• ▍Operating income +42,1% YoY
• ▍Net income +42,4% YoY
• ▍Free cash flow +42,5% YoY

Operating income +10,8% YoY; Net income +12,4% YoY.

• ▍Operating income +10,8% YoY
• ▍Net income +12,4% YoY
• ▍Free cash flow +12,7% YoY

Operating income −130,7% YoY; Net income −121,6% YoY.

• ▍Operating income −130,7% YoY
• ▍Net income −121,6% YoY
• ▍Free cash flow −118,0% YoY

Operating income -$12.4M.

• ▍Operating income -$12.4M